Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody

Molecules and Cells

Volumn 24, Issue 1, 2007, Pages 132-138

  Ju, Seong A ^a   Park, Sang Min ^a   Lee, Sang Chul ^a   Kwon, Byoung S ^a   Kim, Byung Sam ^a  

^a University of Ulsan   (South Korea)

Author keywords

4 1BB; Anti tummor immunity; Melanoma; Th1 cytokines

Indexed keywords

CD137 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; IN VITRO STUDY; LUNG TUMOR; LYMPH NODE; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN; TH1 CELL; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11C; ANTIGENS, CD137; CD8-POSITIVE T-LYMPHOCYTES; INTERFERON TYPE II; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

MUS;

EID: 35048865259     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Alleva, D. G., Burger, C. J., and Elgert, K. D. (1994) Tumor-induced regulation of suppressor macrophage nitric oxid and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J. Immunol. 153, 1674-1686.
2. Betts, M. R., Brenchley, J. M., Price, D. A., De Rosa, S. C., Douck, D. C., et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281, 65-78.
3. Boon, T., De Plaen, E., Lurquin, C., Van den Eynde, B., and van der Bruggen, P. (1992) Identification of tumor rejection antigens recognized by T lymphocytes. Cancer Surv. 13, 23-37.
4. Chang, S. K., Park, B., Shin, J., Ahn, J. H., Kim, I. H., et al. (2002) Proto-oncogene PML enhances antigen presentation by MHC class I molecules in human lung cancer cells. Mol. Cells 14, 130-135.
5. Ghosh, P., Komschlies, K. L., Cippitelli, M., Longo, D. L., Subleski, J., et al. (1995) Gradual loss of T-helper 1 populations in spleens of mice during progressive tumor growth. J. Nat. Cancer Inst. 87, 1478-1483.
6. + T cells in vivo. J. Immunol. 154, 5684-5693.
7. Jang, I. K., Lee, Z. H., Kim, H. H., Hill, J. M., Kim J. D., et al. (2001) A Novel leucine-rich repeat protein (LRR-1): Potential involvement in 4-IBB-mediated signal transduction. Mol. Cells 12, 304-312.
8. Jang, Y. J., Nam, S. Y., Kim, M. S., Seong, R. H., Park, Y. S., et al. (2002) Simultaneous expression of allogenic class II MHC and B7.1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity. Mol. Cells 13, 130-136.
9. Ju, S. A., Lee, S. C., Kwon, T. H., Heo, S. K., Park, S. M., et al. (2005) Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol. Cell Biol, 83, 344-351.
10. + T cells. Cell. Immunol. 238, 76-86.
11. Kiertscher, S. M., Luo, J., Dubinett, S. M., and Roth, M. D. (2000) Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J. Immunol. 164, 1269-1276.
12. Kobayashi, M., Kobayashi, H., Pollard, R. B., and Suzuki, F. (1998) A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J. Immunol. 160, 5869-5873.
13. Li, Q., Carr, A., Ito, F., Teitz-Tennenbaum, S., and Chang, A. E. (2003) Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res. 63, 2546-2552.
14. Maeda, H. and Shiraishi, A. (1996) TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol. 156, 73-78.
15. Melero, L, Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., et al. (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule can eradicate established tumors. Nat. Med. 3, 682-685.
16. McAdam, A. J., Pulaski, B. A., Harkins, S. S., Hutter, E. K., Lord, E. M., et al. (1995) Synergistic effects of co-expression of the Thl-cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells. Int. J. Cancer 61, 628-634.
17. Miller, R. E., Jones, J., Le,, T., Whitmore, J., Boiani, N., et al. (2002) 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 169, 1792-800.
18. Park, E. K., Soh, B. Y., Jang, Y S., Park, J. H., and Chung, G. H. (2001) Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virus. Mol. Cells 12, 50-56.
19. Pulendran, B., Lingappa, J., Kennedy, M. K., Smith, J., Teepe, M., et al. (1997) Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic; cell subsets in FLT3 ligand-treated mice. J. Immunol. 159, 2222-2231.
20. Seo, S. K., Choi, J. H., Kim, Y. H., Kang, W. J., Park, H. Y., et al. (2004) 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med 10, 1088-1094.
21. Taraban, V. Y., Rowley, T. F., O'Brien, L., Chan, H. T., Haswell, L. E., et al. (2002) Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur. J. Immunol. 32, 3617-3627.
22. Vinay, D. S. and Kwon, B.S. (1998) Role of 4-1BB in immune responses. Semin. Immunol. 10, 481-489
23. Weber, J. S. and Rosenberg, S. A. (1998) Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 48, 5818-5824.
24. Wilcox, R. A., Flies D. B., Zhu, G.., Johnson, A. J., Tamada, K., et al. (2002) Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109, 651-659.
25. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. JEM 201, 779-791.